As supply chain vulnerabilities intensify and competition accelerates, the cost of this underutilization could risk India's competitive position.

HANGZHOU, ZHEJIANG, CHINA, January 16, 2026 /EINPresswire.com/ -- The pharmaceutical industry is undergoing a period of ...

Enveda has been using AI to power its drug discovery platform for several years. The company injected $230 million into funding the process through June 2024. Meanwhile, Phlow grew its analytical ...

According to multiple recent market analyses, the global API market is experiencing steady growth. One comprehensive forecast projects the global active pharmaceutical ingredient market to expand from ...

The genesis of a small molecule drug is often an international affair. The medication might begin its life at an active pharmaceutical ingredient (API) manufacturing facility in Puerto Rico, then stop ...

Technological innovations throughout the past several decades have transformed the pharmaceutical manufacturing process from traditional batch production to ...

LONGMONT, Colo.--(BUSINESS WIRE)--Avista Pharma Solutions, Inc. (“Avista Pharma”) has completed facility upgrades that effectively double the company’s API manufacturing capacity at its Longmont, ...

This investment comes as LGM Pharma experiences sustained growth in prescription drug projects, including 505(b)(2) and Abbreviated New Drug Application (ANDA) programs. The Rosenberg facility ...

What not to do with active pharmaceutical ingredient (API) batch records? Tear them out of a company logbook ahead of an FDA inspection, for one. Earlier this month, Indian drugmaker Indiana Chem-Port ...

SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to Siegfried (Zofingen Switzerland)The ...

Ardena has completed the process of divesting its active pharmaceutical ingredient (API) site in Södertälje, Sweden, to Nanologica AB.

Market valued at $72.4M in 2024, projected 7.30% CAGR growth driven by pharmaceutical API synthesis, food-grade ...